Last reviewed · How we verify

BLINATUMOMAB — Competitive Intelligence Brief

BLINATUMOMAB (BLINATUMOMAB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed CD19, CD3 Monoclonal antibody Live · refreshed every 30 min

Target snapshot

BLINATUMOMAB (BLINATUMOMAB). Blinatumomab binds CD19 on B-cells and CD3 on T-cells, activating T-cells to lyse CD19+ cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BLINATUMOMAB TARGET BLINATUMOMAB marketed CD19, CD3 2014-01-01
Ponatinib + Blinatumomab Ponatinib + Blinatumomab Gruppo Italiano Malattie EMatologiche dell'Adulto phase 3 Tyrosine kinase inhibitor, Bispecific monoclonal antibody BCR-ABL1, CD19, CD3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BLINATUMOMAB — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl1742992. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: